BLM and cervical cancer: The Amor-Gueret laboratory made one of the first observations that expression of the RecQ DNA helicase defective in Bloom’s syndrome (BLM) is regulated when they analyzed the level of BLM protein by immunoblotting of extracts from cycling human cervical cancer (HeLa) cells either untreated or treated with the replication inhibitors hydroxyurea (HU) or aphidicolin (APH) [30].